Why is "B-cell activating factor" trending?

Search Interest Perspective

• BAFF/APRIL Inhibition Shows Promise for Reducing Proteinuria in IgA Nephropathy - Physician's Weekly
• Dysregulated B cell homeostasis and the involvement of B cell-activating factor in the progression of diabetic retinopathy - Nature
• Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine - Cureus
• Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD - The American Journal of Managed Care
• FDA Approves First Dual Inhibitor Treatment for IgA Nephropathy - Drug Topics
• Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs - Fierce Biotech
• Competition Builds for Novel IgA Nephropathy Approach - MedPage Today
• Trutakna Approved to Reduce Proteinuria in Primary IgA Nephropathy - MPR - Medical Professionals Reference
• B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds - The American Journal of Managed Care
• Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia - Nature
• B-Cell Activating Factor Receptor CAR T Therapy Holds Promise for CLL - The American Journal of Managed Care
• Depletion of B cell-activating factor attenuates hepatic fat accumulation in a murine model of nonalcoholic fatty liver disease - Nature
• B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? - Nature
• Immunology & Cell Biology | ASI Journal - Wiley Online Library
• Benlysta Found to Effectively Change B-cell Levels - Lupus Foundation of America
• A serum B-lymphocyte activation signature is a key distinguishing feature of the immune response in sarcoidosis compared to tuberculosis - Nature
• Proof-of-concept study evaluating humoral primary immunodeficiencies via CJ:KREC ratio and serum BAFF level - Nature
• B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality - Nature
• FDA Makes Ianalumab a Breakthrough Therapy for Sjögren Disease - Medscape
• Novel Lupus Drugs Continue to Shine in Extended Early Data - MedPage Today
• PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure - BioSpace
• Advancement in CAR-T cell therapy for resistant B cell cancers - Mayo Clinic
• Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - BioSpace
• Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma - Baishideng Publishing Group
• HS Pipeline Watch: Zura Bio Launches Global Phase 2 Study of Its Dual IL-17A and BAFF Inhibitor in Adults With HS - thedermdigest.com
• Synovial cell death is regulated by TNF-α-induced expression of B-cell activating factor through an ERK-dependent increase in hypoxia-inducible factor-1α | Cell Death & Disease - Nature
• First-in-Class Drug Approved for IgA Nephropathy - MedPage Today
• Could CAR-T cell therapy improve kidney transplants? - Mayo Clinic News Network
• Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace
• A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers - Nature
• BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors - Nature
• Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy - Nasdaq
• FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy - Eastern Progress
• Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus - Nature
• Ianalumab's Success in Phase III Trials Marks a Turning Point in Sjogren's Disease - MedPage Today
• Possible interplay between estrogen and the BAFF may modify thyroid activity in Graves’ disease - Nature
• BAFF attenuates oxidative stress-induced cell death by the regulation of mitochondria membrane potential via Syk activation in WiL2-NS B lymphoblasts - Nature
• Regulation of B cell activating factor (BAFF) receptor expression by NF-κB signaling in rheumatoid arthritis B cells - Nature
• Regulatory and effector B cells control scleroderma - Medical Xpress
• Novel Biologic for Sjogren's Clears Penultimate Hurdle - MedPage Today
• Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding - MedCity News
• Overexpression of the Cytokine BAFF and Autoimmunity Risk - NEJM
• New Sjogren’s CAR T-Cell Therapy Focus of Luminary, Case Western Pact - Sjogren's Disease News
• The activation of BAFF/APRIL system in spleen and lymph nodes of Plasmodium falciparum infected patients - Nature
• Researchers develop a faster, stronger rabies vaccine - Medical Xpress
• Advances in the treatment of IgA nephropathy | Durlik | Renal Disease and Transplantation Forum - Via Medica Journals
• Telitacicept Improves Clinical Response but Increases Infection Risk in Adults with Active Systemic Lupus Erythematosus: Phase 3 Trial Results - Vera Health
• BAFF is involved in macrophage-induced bortezomib resistance in myeloma - Nature
• BAFF knockout improves systemic inflammation via regulating adipose tissue distribution in high-fat diet-induced obesity - Nature
• BAFF upregulates CD28/B7 and CD40/CD154 expression and promotes mouse T and B cell interaction in vitro via BAFF receptor - Nature
• Blisibimod: Potential Treatment for Systemic Lupus Erythematosus - Lupus News Today
• IFN type I and II induce BAFF secretion from human decidual stromal cells | Scientific Reports - Nature
• First lupus breakthrough in 50 years - Medical Xpress
• Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1 - Nature
• Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy - STT Info
• US FDA approves first-in-class treatment for kidney disease - MyJoyOnline